A Prospective Multicenter Clinical Study on the Efficacy and Safety of the Zirconia Ceramic Hip Joint Prosthesis System After Its Market Launch

ConditionsTHAProsthesis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorPeking University Third Hospital

About this trial

This study adopted a prospective, multi-center, single-group target value trial design to evaluate the safety and efficacy of the hip joint prosthesis system produced by Beijing Anshou Technology Co., Ltd. in total hip arthroplasty. This clinical study selected seven clinical centers and recruited 290 subjects. Each center competed for enrollment, with the requirement that each center should undertake no less than 8 cases and no more than half of the total cases. The enrollment stopped when the total number of cases met the design requirements. After the patients signed the informed consent form, they entered the screening process. After the screening was successful, the hip joint prosthesis system produced by Beijing Anshou Technology Co., Ltd. was implanted, and follow-up was conducted for the patients at "before surgery, on the day of surgery, immediately after surgery until discharge, 2 weeks after surgery, 6 weeks after surgery, 3 months after surgery, 6 months after surgery, and 12 months after surgery." The demographic information and various evaluation indicators of the subjects were collected.

Eligibility criteria

Qualifiers

The patient's age ranges from 18 to 80 years old (inclusive), with no gender restrictions.

The patient's bones have matured.

The patient is indicated for hip replacement surgery

The subjects participating in the study were undergoing hip replacement for the first time

Disqualifiers

There are contraindications for hip replacement surgery

It is known that the patient has a history of allergy to one or more implant materials

Pregnant or lactating women

Hip dysplasia is classified into CROWE grades 3 and 4

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

290 Participants
are grouped into 1 trial group

Sponsors and collaborators

Peking University Third Hospital

Lead sponsor

Peking Union Medical College Hospital

Collaborator

Peking University First Hospital

Collaborator

Beijing Friendship Hospital

Collaborator

China-Japan Friendship Hospital

Collaborator

Peking University Shougang Hospital

Collaborator

Peking University People's Hospital

Collaborator